A phase III trial of obinutuzumab β shows striking efficacy in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder. The findings reinforce B cell depletion as a therapeutic principle while raising a more fundamental question: which B cell populations must be depleted, and how completely? This is a preview of subscription content, access via your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription Receive 12 print issues and online access Prices may be subject to local taxes which are calculated during checkout Lennon, V.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004). Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
Med. 381, 614–625 (2019). Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 19, 298–306 (2020).
Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Med. https://doi.org/10.1038/s41591-026-04583-4 (2026). Article PubMed PubMed Central Google Scholar Chihara, N. et al.
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. USA 108, 3701–3706 (2011). Article CAS PubMed PubMed Central Google Scholar Hoshino, Y. et al.
Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder. Neuroinflam. 19, 6 (2022). Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.
Extract — continue reading at the source.
